RYBOX Mutual Fund

RYBOX Mutual Fund

NAV$75.38

Fund Essentials - as of Mar 31, 2026

Net Assets
$16M
Expense Ratio
1.64%
Dividend Yield (Current)
12.78%
Holdings
75
Inception Date
Sep 1, 2004
Fund Family
Rydex Funds
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+18.77%
1 Year+79.03%
3 Year+29.14%
5 Year+11.38%
10 Year+13.02%

Asset Allocation

Stocks: 99.55%
Bonds: 0.44%

Top Holdings

View All →
TickerNameWeight
ABBVAbbvie Inc Health Care7.39%
AMGNAmgen Inc. Com5.23%
GILDGilead Sciences Inc4.96%
VRTXVertex Pharmaceuticals Inc4.01%
REGNRegeneron Pharmaceuticals, Inc.3.56%
Top 10 Concentration: 36.65%Report Date: Mar 31, 2026
Download all 75 holdings for RYBOX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
12.78%
Frequency
Annually
Latest Distribution
$15.77
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO
FundXLS Pro
See how RYBOX ranks against its peers
Category rank, peer-average returns and outperformance, updated daily.
X-ray my whole portfolio$45/quarter Pro · Cancel anytime
From MarketXLS, trusted since 2014.

RYBOX Mutual Fund Overview

RYBOX Mutual Fund (Rydex Biotechnology Fund Class A) is managed by Rydex Funds with $16.1M in net assets. RYBOX expense ratio is 1.64%, holding 75 positions across sectors including Health Care. Inception date: 2004-09-01.

RYBOX performance shows a YTD return of 18.77%. The 1-year return is 79.03% and the 5-year return is 11.38%. RYBOX dividend yield stands at 12.78%, paid annually.

RYBOX top holdings include Abbvie Inc Health Care (7.4%), Amgen Inc. Com (5.2%), Gilead Sciences Inc (5.0%), Vertex Pharmaceuticals Inc (4.0%), Regeneron Pharmaceuticals, Inc. (3.6%). Go to all RYBOX holdings, RYBOX sectors, or RYBOX dividends.

RYBOX can be compared against other funds. Use RYBOX overlap to find shared positions, or RYBOX vs another fund for a side-by-side view. RYBOX alternatives are available via the screener, along with tax-loss harvesting opportunities.